CITIUS ONCOLOGY, INC.CTOREarnings & Financial Report
Nasdaq
NextMay 14, 2026
CTOR Q1 2026 Key Financial Metrics
Revenue
$3.9M
Gross Profit
$3.2M
Operating Profit
$-5.3M
Net Profit
$-5.5M
Gross Margin
80.0%
Operating Margin
-133.2%
Net Margin
-140.3%
YoY Growth
N/A
EPS
$-0.06
Financial Flow
CITIUS ONCOLOGY, INC. Q1 2026 Financial Summary
CITIUS ONCOLOGY, INC. reported revenue of $3.9M for Q1 2026, with a net profit of $-5.5M (-140.3% margin). Cost of goods sold was $789.2K, operating expenses totaled $8.4M.
Key Financial Metrics
| Total Revenue | $3.9M |
|---|---|
| Net Profit | $-5.5M |
| Gross Margin | 80.0% |
| Operating Margin | -133.2% |
| Report Period | Q1 2026 |
Income Statement
| Q1 2026 | |
|---|---|
| Revenue | $3.9M |
| YoY Growth | N/A |
Balance Sheet
| Q1 2026 | |
|---|---|
| Assets | $110.0M |
| Liabilities | $51.6M |
| Equity | $58.4M |
Cash Flow
| Q1 2026 | |
|---|---|
| Operating CF | $-7.4M |